- Home
- RYAM vs YMAB Comparison
RYAM vs YMAB Comparison
Compare RYAM & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYAM
- YMAB
- Stock Information
- Founded
- RYAM 1926
- YMAB 2015
- Country
- RYAM United States
- YMAB United States
- Employees
- RYAM N/A
- YMAB N/A
- Industry
- RYAM Paper
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RYAM Basic Materials
- YMAB Health Care
- Exchange
- RYAM Nasdaq
- YMAB Nasdaq
- Market Cap
- RYAM 255.7M
- YMAB 192.4M
- IPO Year
- RYAM N/A
- YMAB 2018
- Fundamental
- Price
- RYAM $4.22
- YMAB $4.30
- Analyst Decision
- RYAM Buy
- YMAB Buy
- Analyst Count
- RYAM 1
- YMAB 11
- Target Price
- RYAM $6.00
- YMAB $17.55
- AVG Volume (30 Days)
- RYAM 461.4K
- YMAB 204.2K
- Earning Date
- RYAM 08-05-2025
- YMAB 08-11-2025
- Dividend Yield
- RYAM N/A
- YMAB N/A
- EPS Growth
- RYAM N/A
- YMAB N/A
- EPS
- RYAM N/A
- YMAB N/A
- Revenue
- RYAM $1,598,619,000.00
- YMAB $88,658,000.00
- Revenue This Year
- RYAM N/A
- YMAB N/A
- Revenue Next Year
- RYAM $3.23
- YMAB $15.15
- P/E Ratio
- RYAM N/A
- YMAB N/A
- Revenue Growth
- RYAM 2.20
- YMAB 4.92
- 52 Week Low
- RYAM $3.45
- YMAB $3.55
- 52 Week High
- RYAM $10.28
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- RYAM 59.08
- YMAB 42.53
- Support Level
- RYAM $3.74
- YMAB $3.90
- Resistance Level
- RYAM $4.18
- YMAB $5.33
- Average True Range (ATR)
- RYAM 0.16
- YMAB 0.36
- MACD
- RYAM 0.04
- YMAB -0.08
- Stochastic Oscillator
- RYAM 91.49
- YMAB 27.97
About RYAM Rayonier Advanced Materials Inc.
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.